But deals such as General Electric's transactions with Iran and Syria, or the Russian subsidiary of IBM moving its power and computers to weapons manufacturing facilities could cause unease with investors.
Earlier this month, a U.S. subsidiary of Ranbaxy pleaded guilty to felony charges relating to adulterated drugs made at the two manufacturing facilities, according to the Justice Department.